Decades of experience in orphan drug acquisition and development supported by a deep list of industry contacts, cutting edge IT, the services of leading scientists and executives mean there is no firm better able than Daedalus to promote a firm’s orphan drug success.
Smaller clients are well-advised to avoid wasting money over-bidding for late-stage assets. If advanced assets are desired by firms of limited means for whatever reason, they should be sought outside conventional deal structures.
1/3 of compounds in development for orphan disorders are repurposed from their original indications.
Business Development
Decades of experience in orphan drug acquisition and development supported by a deep list of industry contacts, cutting edge IT, the services of leading scientists and executives mean there is no firm better able than Daedalus to promote a firm’s orphan drug success.
The fate of several hundred pivotal-stage drug candidates collides with the reality that yearly the FDA will approve only a few dozen new drugs. These are daunting odds, and during the years a compound spends crawling through clinical development no CEO will feel that a little more time and money at the start would not have been good investment.
Just as a strong chess player knows superior early position can be developed to crush an opponent. And a talented general knows that “shaping the battlefield” in his favor can deliver victory. Thorough research before acquiring a compound for clinical development can be the difference between extraordinary success and expensive, drawn-out failure.
1. Being first to an asset is more important in orphan drugs than elsewhere in biopharma, since the first approval enjoys exclusivity.
2. Smaller clients are well-advised to avoid wasting money over-bidding for late-stage assets. If advanced assets are desired by firms of limited means for whatever reason, they should be sought outside conventional deal structures.
3. Firms should offer early support to promising academic programs. A modest sum can establish a firm in a dominant position before the interest of larger firms in an asset goes on the boil.
4. Support early investigator-sponsored trials to expedite the development pathway of desirable assets.
5. Evaluate all available drugs and drug candidates for repositioning. 1/3 of compounds in development for orphan disorders are repurposed from their original indications.
6. Look to acquire/partner/license technology that will generate credible drug candidates.
7. Employing Daedalus as needed is more effective and less expensive than maintaining a substantial in-house business development establishment.